Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity- AIM 1
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Keegan M Stewart
- Phone Number: 480-301-4164
- Email: stewart.keegan@mayo.edu
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Recruiting
- Mayo Clinic in Arizona
-
Principal Investigator:
- Elena De Filippis, MD,PhD
-
Contact:
- Stewart Keegan
- Phone Number: 480-301-4164
- Email: stewart.keegan@mayo.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Undergoing gastric bypass surgery
- Confirmed AUROC F=0 or F>2 liver fibrosis
- Age 30-70 years
- BMI greater than 40 kg/m2
- Negative pregnancy test (female only)
- Lab Values: Normal TSH
Exclusion Criteria:
- Autoimmune diseases
- Hepatitis B or C positive
- Heavy alcohol use
- Active smoking history
- Active cancer history
- History of asthma
- History of COPD
- Taking Plavix or Coumadin
- Blood donation within past 2 months
- Glucocorticoid Therapy
- Taking antihistamine on regular basis
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Weight loss surgery
Gastric bypass surgery will be followed by weight loss as standard of care.
Liver fibrosis by elastography will be determined before surgery.
|
Evaluate liver fibrosis by elastography before gastric bypass surgery.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Liver fibrosis
Time Frame: Baseline
|
evaluate the liver fibrosis by elastography before surgical intervention
|
Baseline
|
|
Adipose tissue inflammation
Time Frame: Baseline
|
Evaluate markers of adipose tissue inflammation by mRNA levels
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Elena Anna O De Filippis, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nutrition Disorders
- Metabolic Diseases
- Overnutrition
- Body Weight
- Digestive System Diseases
- Glucose Metabolism Disorders
- Liver Diseases
- Hyperinsulinism
- Overweight
- Fatty Liver
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Obesity
- Non-alcoholic Fatty Liver Disease
- Insulin Resistance
- Obesity, Morbid
- Therapeutics
- Surgical Procedures, Operative
- Digestive System Surgical Procedures
- Anastomosis, Surgical
- Bariatrics
- Obesity Management
- Gastroenterostomy
- Gastric Bypass
- Bariatric Surgery
Other Study ID Numbers
Other Study ID Numbers
- 18-004615
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.